STERIS plc (STE)
| Market Cap | 20.50B -16.7% |
| Revenue (ttm) | 6.04B +8.4% |
| Net Income | 805.00M +24.5% |
| EPS | 8.18 +25.3% |
| Shares Out | 97.50M |
| PE Ratio | 25.71 |
| Forward PE | 18.35 |
| Dividend | $2.76 (1.31%) |
| Ex-Dividend Date | Sep 4, 2026 |
| Volume | 778,998 |
| Open | 212.64 |
| Previous Close | 213.66 |
| Day's Range | 210.19 - 214.02 |
| 52-Week Range | 195.14 - 269.44 |
| Beta | 0.91 |
| Analysts | Buy |
| Price Target | 263.13 (+25.13%) |
| Earnings Date | Nov 4, 2026 |
About STE
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, e... [Read more]
Financial Performance
In fiscal year 2026, STERIS's revenue was $5.94 billion, an increase of 8.73% compared to the previous year's $5.46 billion. Earnings were $782.30 million, an increase of 27.29%.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for STE stock is "Buy." The 12-month stock price target is $263.13, which is an increase of 25.13% from the latest price.
News
STERIS Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Resilient healthcare demand, recurring revenue dominance, and strong endoscopy growth underpin stable mid to high single-digit top-line and double-digit bottom-line targets. Expansion in Europe, automation investments, and margin improvement initiatives support a positive multi-year outlook.
STERIS to Present at the Morgan Stanley Healthcare Conference
Dublin, Ireland, Sept. 01, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will participate in the Morgan Stanley Healthcare Conference in New York ...
Steris price target lowered to $270 from $275 at UBS
UBS lowered the firm’s price target on Steris (STE) to $270 from $275 and keeps a Buy rating on the shares.
STERIS Earnings Call Transcript: Q1 2027
Revenue grew 7% year-over-year with strong margin expansion and double-digit EPS growth. Healthcare and Life Sciences segments delivered robust organic growth, while a $600 million investment in a new chemistry center was announced. Fiscal 2027 guidance and dividend growth were reaffirmed.
STERIS Earnings release: Q1 2027
STERIS released its Q1 2027 earnings on August 6, 2026, summarizing the period's financial results.
STERIS Quarterly report: Q1 2027
STERIS has published its Q1 2027 quarterly earnings report on August 6, 2026.
Steris announces targeted restructuring plan
Steris (STE) is announcing a targeted restructuring plan in connection with its recent announcement to consolidate manufacturing and distribution for formulated chemistries to a new Center of Excellen...
Steris reports Q1 adjusted EPS $2.59, consensus $2.49
Reports Q1 revenue $1.5B, consensus $1.5B. “We are pleased with our performance in the first quarter,” said Dan Carestio, President and CEO of STERIS (STE). “Our first quarter results reflected…
Steris backs FY27 adjusted EPS view of $11.10-$11.30, consensus $11.16
Steris (STE) said: “The Company is reiterating its prior guidance for revenue and earnings for fiscal 2027. This includes as reported revenue growth of 7-8% and constant currency organic revenue…
STERIS Announces Financial Results for Fiscal 2027 First Quarter
DUBLIN, IRELAND, Aug. 05, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2027 first quarter ended June 30, 2026. Total rev...
Steris management to meet virtually with KeyBanc
Virtual Meeting to be held on August 13 hosted by KeyBanc.
Steris to invest $600M in North Carolina facility
Steris (STE) announced that it will be investing $600M to build a formulated chemistries manufacturing and distribution Center of Excellence in North Carolina, near the Raleigh-Durham Research Triangl...
Steris to invest $600 million in new North Carolina chemicals manufacturing hub
Medical equipment maker Steris said on Wednesday it will invest $600 million to build a manufacturing and distribution hub in North Carolina for chemicals used by healthcare and pharmaceutical custo...
STERIS To Invest $600 Million to Build a Formulated Chemistries Manufacturing and Distribution Center of Excellence in North Carolina
• This Formulated Chemistries Center of Excellence will support sterilization and disinfection for the global Healthcare and Pharmaceutical industries
Steris increases quarterly dividend to 69c per share
Steris (STE) announced that the company will distribute a quarterly interim dividend of 69c per share. This represents a 6c increase in the dividend. The dividend is payable on September…
STERIS Raises Dividend to $0.69 per share
DUBLIN, IRELAND, July 30, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.69 per share. ...
Steris initiated with a Buy at UBS
UBS analyst Patrick Wood initiated coverage of Steris (STE) with a Buy rating and $275 price target Steris is misunderstood by investors, with current concerns around capital spending and Applied…
STERIS to Host a Conference Call for Fiscal 2027 First Quarter on August 6, 2026
DUBLIN, IRELAND, July 27, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2027 first quarter resul...
STERIS Proxy statement: Proxy filing
STERIS filed a proxy statement on June 11, 2026, providing details for shareholder voting and corporate governance matters.
STERIS Proxy statement: Proxy filing
STERIS filed a proxy statement on June 11, 2026, providing details for shareholder voting and corporate governance matters.
Steris price target lowered to $269 from $291 at KeyBanc
KeyBanc analyst Brett Fishbin lowered the firm’s price target on Steris (STE) to $269 from $291 given lower peer multiples, while keeping an Overweight rating on the shares. The firm…
STERIS Earnings Call Transcript: Q4 2026
Record fiscal 2026 results featured 9% revenue growth and 10% adjusted EPS growth, with all segments achieving milestones. Fiscal 2027 guidance calls for 7%-8% revenue growth, 9%-11% EPS growth, and continued investment in automation, M&A, and share buybacks.
STERIS Earnings release: Q4 2026
STERIS released its Q4 2026 earnings on May 12, 2026, summarizing the period's financial results.
STERIS Annual report: Q4 2026
STERIS has published its Q4 2026 annual report on May 12, 2026.
STERIS Slides: Investor presentation
STERIS has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.